Meinox İlaç Teknolojileri

About This Project

Meinox: Developing New Drug Technologies for Cancer and Malignancies

Meinox develops new drug technologies for various types of cancer and malignancies. The founder is Associate Professor Dr. Fatih Kocabaş. MEISi is Meinox’s first innovative drug product. MEISi targets MEIS proteins, which play a critical role in cellular and cancer metabolism, as well as being associated with cardiovascular diseases, diabetes, and obesity. The major contribution of the drug in the R&D sector is providing tools to modulate the molecular mechanisms of these diseases. MEISi stands out with its potential to offer personalized treatment in medical and veterinary applications.

Meinox Pharmaceutical Technologies Inc. was established in 2019 with TÜBİTAK BiGG support. In 2019, Meinox won the EU Horizon SME support and was ranked 17th among 3,275 European companies, and 1st in Turkey, positioning itself as one of the best startups in Europe. Meinox, which took the stage at Big Bang 2019, was awarded the biggest prizes by the Istanbul Chamber of Industry and the Elginkan Foundation. Meinox Pharmaceutical Technologies Inc. continues its activities in the ITU Magnet & Biotechnology Laboratory, focusing on RUO production, veterinary applications, and drug formulation development.